Roche Emerging From Difficult Covid Comparisons With Solid Pharma and Diagnostics Prospects
We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...
Targeted Oncology1d
Response Time and BRAF Status Factor Into IO Selection for Melanoma
During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 ...
In HER2+ colorectal cancer, anti-HER2 therapy may be less toxic alternative
Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...
BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight
The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...
Zawya2d
Diatech Pharmacogenetics expands collaboration with Merck
JESI, Italy-- (BUSINESS WIRE/AETOSWire): Diatech Pharmacogenetics announced an expansion of its collaboration with Merck ...
Diatech Pharmacogenetics Expands Collaboration with Merck to Enhance Patient Access to Personalized Medicine in the Middle East and Africa
Diatech Pharmacogenetics announced an expansion of its collaboration with Merck Serono Middle East Ltd., affiliates of Merck KGaA ("Merck"). The collaboration aims to improve patient access to RAS ...
Pwllheli: Gwaith adeiladu 'annioddefol' wedi 'difrodi tai'
Mae pobl sy'n byw yn nhref Pwllheli, Gwynedd yn honni fod gwaith adeiladu "annioddefol" i godi fflatiau gerllaw wedi achosi ...
Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
Detailed price information for Zentalis Pharmaceuticals Inc (ZNTL-Q) from The Globe and Mail including charting and trades.
appliedclinicaltrialsonline2d
Pfizer Shares Positive Data from Phase III BREAKWATER Trial of Braftovi Combination Following Accelerated Approval
Being evaluated for the treatment of metastatic colorectal cancer, the combination regimen achieved an objective response ...
Lutris Pharma Secures $30 Million Financing to Advance the Development of Biopharmaceutical to Improve Anti-Cancer Drug Effectiveness
Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous ...
Erasca: Future 'Streamlined' But Still Uncertain
Erasca is a biotech company focused on developing therapies for RAS/MAPK pathway-driven cancers with a strong financial ...
Pharmabiz3d
Pfizer’s BREAKWATER trial of Braftovi combo regimen demonstrates improved response in patients with BRAF V600E-mutant metastatic colorectal cancer
Pfizer’s BREAKWATER trial of Braftovi combo regimen demonstrates improved response in patients with BRAF V600E-mutant metastatic colorectal cancer: New York Tuesday, January 28, ...